160 related articles for article (PubMed ID: 34677008)
21. Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice.
Zhou ST; Cui W; Kong L; Yang X
Curr Med Sci; 2022 Jun; 42(3):513-519. PubMed ID: 35451807
[TBL] [Abstract][Full Text] [Related]
22. Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease.
Ozturk O; Colak Y; Senates E; Yilmaz Y; Ulasoglu C; Doganay L; Ozkanli S; Oltulu YM; Coskunpinar E; Tuncer I
World J Gastroenterol; 2015 Jul; 21(26):8096-102. PubMed ID: 26185381
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathological Profile and Outcome of a Large Cohort of Patients with Nonalcoholic Fatty Liver Disease from South Asia: Interim Results of the Indian Consortium on Nonalcoholic Fatty Liver Disease.
Duseja A; Singh SP; Mehta M; Shalimar ; Venkataraman J; Mehta V; Devadas K; Kar SK; Goyal O; Nagral A; Saigal S; Nijhawan S; Praharaj D; Shukla A; Sharma B; Narayanasamy K; Kumar P; Rao PN; Arora A; Mehta R; Asati P; Ranjan P; Koshy A; Alam S; Mukewar S; Mukewar S; Mohan Prasad VG; Rastogi M; Sanyal AJ
Metab Syndr Relat Disord; 2022 Apr; 20(3):166-173. PubMed ID: 35085026
[No Abstract] [Full Text] [Related]
24. Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease.
Jiang ZG; Tapper EB; Kim M; Connelly MA; Krawczyk SA; Yee EU; Herman MA; Mukamal KJ; Lai M
J Clin Gastroenterol; 2018; 52(5):444-451. PubMed ID: 28362682
[TBL] [Abstract][Full Text] [Related]
25. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease.
Maleki I; Aminafshari MR; Taghvaei T; Hosseini V; Rafiei A; Torabizadeh Z; Barzin M; Orang E
World J Gastroenterol; 2014 Sep; 20(35):12566-73. PubMed ID: 25253959
[TBL] [Abstract][Full Text] [Related]
26. Serum ferritin levels predict histological severity in patients with nonalcoholic fatty liver disease in India.
Parikh P; Patel J; Ingle M; Sawant P
Indian J Gastroenterol; 2015 May; 34(3):200-8. PubMed ID: 26108652
[TBL] [Abstract][Full Text] [Related]
27. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.
Bril F; Sninsky JJ; Baca AM; Superko HR; Portillo Sanchez P; Biernacki D; Maximos M; Lomonaco R; Orsak B; Suman A; Weber MH; McPhaul MJ; Cusi K
J Clin Endocrinol Metab; 2016 Feb; 101(2):644-52. PubMed ID: 26672634
[TBL] [Abstract][Full Text] [Related]
28. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
[No Abstract] [Full Text] [Related]
29. Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease.
Caussy C; Ajmera VH; Puri P; Hsu CL; Bassirian S; Mgdsyan M; Singh S; Faulkner C; Valasek MA; Rizo E; Richards L; Brenner DA; Sirlin CB; Sanyal AJ; Loomba R
Gut; 2019 Oct; 68(10):1884-1892. PubMed ID: 30567742
[TBL] [Abstract][Full Text] [Related]
30. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
[TBL] [Abstract][Full Text] [Related]
31. PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD.
Grimaudo S; Bartesaghi S; Rametta R; Marra F; Margherita Mancina R; Pihlajamäki J; Kakol-Palm D; Andréasson AC; Dongiovanni P; Ludovica Fracanzani A; Lori G; Männistö V; Pellegrini G; Bohlooly-Y M; Pennisi G; Maria Pipitone R; Spagnuolo R; Craxì A; Lindén D; Valenti L; Romeo S; Petta S
Liver Int; 2021 Feb; 41(2):321-332. PubMed ID: 33091218
[TBL] [Abstract][Full Text] [Related]
32. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes.
Eslam M; Mangia A; Berg T; Chan HL; Irving WL; Dore GJ; Abate ML; Bugianesi E; Adams LA; Najim MA; Miele L; Weltman M; Mollison L; Cheng W; Riordan S; Fischer J; Romero-Gomez M; Spengler U; Nattermann J; Rahme A; Sheridan D; Booth DR; McLeod D; Powell E; Liddle C; Douglas MW; van der Poorten D; George J;
Hepatology; 2016 Jul; 64(1):34-46. PubMed ID: 26822232
[TBL] [Abstract][Full Text] [Related]
33. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients.
Nakahara T; Hyogo H; Yoneda M; Sumida Y; Eguchi Y; Fujii H; Ono M; Kawaguchi T; Imajo K; Aikata H; Tanaka S; Kanemasa K; Fujimoto K; Anzai K; Saibara T; Sata M; Nakajima A; Itoh Y; Chayama K; Okanoue T;
J Gastroenterol; 2014 Nov; 49(11):1477-84. PubMed ID: 24277052
[TBL] [Abstract][Full Text] [Related]
34. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity.
Sookoian S; Castaño GO; Scian R; Mallardi P; Fernández Gianotti T; Burgueño AL; San Martino J; Pirola CJ
Hepatology; 2015 Feb; 61(2):515-25. PubMed ID: 25302781
[TBL] [Abstract][Full Text] [Related]
35. Noninvasive estimation of disease activity and liver fibrosis in nonalcoholic fatty liver disease using anthropometric and biochemical characteristics, including insulin, insulin resistance, and 13C-methionine breath test.
Korkmaz H; Unler GK; Gokturk HS; Schmidt WE; Kebapcilar L
Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1137-43. PubMed ID: 26049707
[TBL] [Abstract][Full Text] [Related]
36. Variations in TM6SF2, PCSK9 and PCSK7 genes and risk of hepatic steatosis after liver transplantation: a cross-sectional study.
Eshraghian A; Moasser E; Azarpira N; Fattahi MR; Nikeghbalian S; Malek-Hosseini SA; Geramizadeh B
BMC Gastroenterol; 2021 Dec; 21(1):458. PubMed ID: 34876018
[TBL] [Abstract][Full Text] [Related]
37. Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis.
Kozumi K; Kodama T; Murai H; Sakane S; Govaere O; Cockell S; Motooka D; Kakita N; Yamada Y; Kondo Y; Tahata Y; Yamada R; Hikita H; Sakamori R; Kamada Y; Daly AK; Anstee QM; Tatsumi T; Morii E; Takehara T
Hepatology; 2021 Nov; 74(5):2452-2466. PubMed ID: 34105780
[TBL] [Abstract][Full Text] [Related]
38. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
[TBL] [Abstract][Full Text] [Related]
39. Association between small dense LDL levels and hepatic fibrosis in patients with nonalcoholic fatty liver disease.
Young Kim S; Mun S; Yu JH; Jin YJ; Ju Suh Y; Cho SH; Lee JW
Medicine (Baltimore); 2022 Sep; 101(37):e30527. PubMed ID: 36123875
[TBL] [Abstract][Full Text] [Related]
40. Noninvasive stratification of nonalcoholic fatty liver disease by whole transcriptome cell-free mRNA characterization.
Chalasani N; Toden S; Sninsky JJ; Rava RP; Braun JV; Gawrieh S; Zhuang J; Nerenberg M; Quake SR; Maddala T
Am J Physiol Gastrointest Liver Physiol; 2021 Apr; 320(4):G439-G449. PubMed ID: 33501884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
